Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
All news
Biotechnology
The US Food and Drug Administration has set up a new program to expedite the development of options to treat COVID-19. 2 April 2020
Biotechnology
Since the first reports of coronavirus (COVID-19) in Wuhan, China in December 2019 there have been more than 823,000 confirmed cases and over 45,000 deaths in 206 countries worldwide. 1 April 2020
Biotechnology
Japanese companies Eisai and Seikagaku Corporation have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate). 1 April 2020
Biotechnology
Japan’s Daiichi Sankyo has entered into a strategic partnership for the non-exclusive use of Ultragenyx Pharmaceutical’s proprietary adeno associated virus (AAV) based gene therapy manufacturing technology. 1 April 2020
Biotechnology
Japan’s SanBio and Ocumension (Hong Kong) Ltd have entered into a business alliance for the research, development and commercialization of innovative stem cell therapies for ophthalmic diseases. 1 April 2020
Biotechnology
Chicago, USA-based ophthalmic specialist Horizon Therapeutics has revealed positive data from a new pooled analysis of Tepezza (teprotumumab-trbw). 1 April 2020
Biotechnology
US biotech Regenxbio announced a new exclusive, worldwide license agreement with Ultragenyx Pharmaceutical, extending the companies’ existing gene therapy partnership announced in October 2018. 1 April 2020
Biotechnology
The US Food and Drug Administration has dropped an investigation into Novartis company AveXis, related to the novel spinal muscular atrophy (SMA) Zolgensma (onasemnogene abeparvovec-xioi). 1 April 2020
Biotechnology
The share price of Californian biotech company Akero Therapeutics was 22% higher by lunchtime on Tuesday after its presentation of data from a NASH study. 31 March 2020
Biotechnology
UK-based biopharmaceutical company Sitryx, focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, has signed an exclusive global licensing and research collaboration with US pharma major Eli Lilly. 31 March 2020
Biotechnology
A New Drug Application (NDA) has been submitted to Japan’s Ministry of Health, Labor and Welfare for the CAR-T therapy axicabtagene ciloleucel to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and related lymphomas. 31 March 2020
Biotechnology
It is predominantly in the USA, Europe and parts of Asia, where advanced new treatments such as cell and gene therapies are being developed, offering hope for better outcomes for patients with diseases like cancer. 31 March 2020
Biotechnology
China-based WuXi Biologics, a contract development and manufacturing organization (CDMO), will focus on overseas development as well as efficiency improvement in 2020, said the firm’s chief executive Chris Chen at a press meeting in Shanghai on Friday, reports The Pharma Letter’s correspondent Wang Fangqing. 31 March 2020
Biotechnology
Bristol-Myers Squibb and bluebird bio have submitted for US approval for idecabtagene vicleucel, a CAR-T cell immunotherapy, in multiple myeloma. 31 March 2020
Biotechnology
USA-based CNS specialist biotech Axsome Therapeutics fell almost 15% after it revealed that its depression drug candidate AXS-05 had failed to achieve its primary endpoint in a Phase III study. 31 March 2020
Biotechnology
A treatment from South Korean company ImmuneMed is being given to COVID-19 pneumonia patients in the Asian country. 30 March 2020
Biotechnology
US biopharma firm Hoth Therapeutics today said it has entered into a non-binding letter of intent (LOI) with Isoprene Pharmaceuticals to acquire the full licensing rights of VNLG-152 novel retinamides (retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. 30 March 2020
Biotechnology
Jiangsu Alphamab Biopharmaceuticals has established strategic partnership with Simcere and 3D Medicines to advance the development and commercialization of a checkpoint inhibitor for programmed cell death ligand-1 (PD-L1), for oncology indications in mainland China. 30 March 2020
Biotechnology
After winning Priority Review from the US regulator in December 2019, Imfinzi (durvalumab) has now been approved as a first-line option for people with extensive-stage small cell lung cancer (ES-SCLC). 30 March 2020
Biotechnology
Numab has expanded its relationship with Japan’s Ono Pharmaceutical by executing another research and option agreement to discover and develop a multi-specific antibody drug candidate for the treatment of various cancers. 30 March 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze